SG11201809778TA - Dna antibody constructs for use against pseudomonas aeruginosa - Google Patents

Dna antibody constructs for use against pseudomonas aeruginosa

Info

Publication number
SG11201809778TA
SG11201809778TA SG11201809778TA SG11201809778TA SG11201809778TA SG 11201809778T A SG11201809778T A SG 11201809778TA SG 11201809778T A SG11201809778T A SG 11201809778TA SG 11201809778T A SG11201809778T A SG 11201809778TA SG 11201809778T A SG11201809778T A SG 11201809778TA
Authority
SG
Singapore
Prior art keywords
international
pseudomonas aeruginosa
pct
subject
dna
Prior art date
Application number
SG11201809778TA
Inventor
David Weiner
Ami Patel
Jian Yan
Original Assignee
Univ Pennsylvania
Wistar Inst
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Wistar Inst, Inovio Pharmaceuticals Inc filed Critical Univ Pennsylvania
Publication of SG11201809778TA publication Critical patent/SG11201809778TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111011111111111111 01011E10 III 011111111011111101111101111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/193101 Al 09 November 2017 (09.11.2017) WIP0 I PCT (51) International Patent Classification: (74) Agent: NGUYEN, Quang, D.; Riverside Law, LLP, Glen- A61K 39/40 (2006.01) C07K 16/12 (2006.01) hardie Corporate Center, 1285 Drummers Lane, Suite 202, C07K 16/00 (2006.01) Wayne, PA 19087 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/031449 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 05 May 2017 (05.05.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (26) Publication Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/332,363 05 May 2016 (05.05.2016) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors; and (71) Applicants: WEINER, David [US/US]; 717 Beacom (84) Designated States (unless otherwise indicated, for every Lane, Merion, PA 19066 (US). PATEL, Ami [US/US]; 1 kind of regional protection available): ARIPO (BW, GH, Rainey Court, Philadelphia, PA 19103 (US). YAN, Man GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — [US/US]; 503 Sheffield Drive, Wallingford, PA 19086 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = = _ _ (54) Title: DNA ANTIBODY CONSTRUCTS FOR USE AGAINST PSEUDOMONAS AERUGINOSA = A = = = oni L, » li.dvy Liog Chain Chain .. , .. Optimization and = Bisi., it, SW111011r:P optina7ation mutt ,.. i into DNA — 1,4,R bt/ftt Chain = t.nctional IgG = = .... tA ' = 14t Exp fes s i o . A qcrarnhly A Secretion = 11131111114 IgGi = < = +.. = D b enters systemic 'isolation; binds to Pseudornones aeruyinose 11 15 % 1\" 1-1 V 0 1-1 01 en 1-1 Figure 1A ---- (57) : Disclosed herein are mono and bispecific DNA antibodies (DMAbs) targeting Pseudomonas aeruginosa. Also disclosed IN ,1 herein is a method of generating a synthetic antibody in a subject by administering the DMAbs to the subject. The disclosure also 0 provides a method of preventing and/or treating Pseudomonas aeruginosa infection in a subject using said composition and method \" of generation. [Continued on next page] WO 2017/193101 Al MIDEDIMOIMMIIMMEMOMEMIOMMIRHIMEMOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))
SG11201809778TA 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa SG11201809778TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332363P 2016-05-05 2016-05-05
PCT/US2017/031449 WO2017193101A1 (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
SG11201809778TA true SG11201809778TA (en) 2018-12-28

Family

ID=60203552

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809778TA SG11201809778TA (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa
SG10202011016WA SG10202011016WA (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202011016WA SG10202011016WA (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa

Country Status (12)

Country Link
US (1) US20190153076A1 (en)
EP (1) EP3452090A4 (en)
JP (2) JP2019520085A (en)
KR (2) KR20230093338A (en)
CN (1) CN110072554A (en)
AU (1) AU2017261374A1 (en)
BR (1) BR112018072716A2 (en)
CA (1) CA3023094A1 (en)
EA (1) EA201892525A1 (en)
MX (1) MX2018013525A (en)
SG (2) SG11201809778TA (en)
WO (1) WO2017193101A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX349886B (en) 2011-06-10 2017-08-17 Medimmune Llc Anti-pseudomonas psl binding molecules and uses thereof.
HUE050985T2 (en) * 2011-11-07 2021-01-28 Medimmune Ltd Combination therapies using anti- pseudomonas psl and pcrv binding molecules
MX2020008062A (en) * 2018-01-31 2020-12-03 Wistar Inst Nucleic acid antibody constructs for use against respiratory syncytial virus.
AU2020322031A1 (en) * 2019-07-31 2022-03-10 The Wistar Institute Of Anatomy And Biology Multivalent DNA antibody constructs and use thereof
AU2020323601A1 (en) * 2019-07-31 2022-03-03 The Wistar Institute Of Anatomy And Biology Multivalent DNA antibody constructs and use thereof
WO2021244421A1 (en) * 2020-06-01 2021-12-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG186017A1 (en) * 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
MX349886B (en) * 2011-06-10 2017-08-17 Medimmune Llc Anti-pseudomonas psl binding molecules and uses thereof.
JP6159724B2 (en) * 2011-08-23 2017-07-05 ロシュ グリクアート アーゲー Bispecific antibodies and tumor antigens specific for T cell activating antigens and methods of use
WO2013036914A1 (en) * 2011-09-08 2013-03-14 University Of Florida Research Foundation, Inc. Materials and methods for modulating immune responses
HUE050985T2 (en) * 2011-11-07 2021-01-28 Medimmune Ltd Combination therapies using anti- pseudomonas psl and pcrv binding molecules
EP2776061B1 (en) * 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
US10072098B2 (en) * 2012-03-02 2018-09-11 Ablynx N.V. Pseudomonas aeruginosa PCRV binding single variable domain antibodies
MX2015005719A (en) * 2012-11-06 2016-01-12 Medimmune Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules.
AU2013358944B2 (en) * 2012-12-13 2016-08-18 Inovio Pharmaceuticals, Inc. DNA antibody constructs and method of using same
EP3080159A4 (en) * 2013-12-13 2017-08-02 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
US20170183397A1 (en) * 2014-05-05 2017-06-29 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (en) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 Treatment of polybacterial infections

Also Published As

Publication number Publication date
KR20230093338A (en) 2023-06-27
CA3023094A1 (en) 2017-11-09
KR20190025826A (en) 2019-03-12
MX2018013525A (en) 2019-06-10
EA201892525A1 (en) 2019-04-30
SG10202011016WA (en) 2020-12-30
JP2023058497A (en) 2023-04-25
BR112018072716A2 (en) 2019-02-19
WO2017193101A1 (en) 2017-11-09
EP3452090A4 (en) 2019-12-18
EP3452090A1 (en) 2019-03-13
JP2019520085A (en) 2019-07-18
CN110072554A (en) 2019-07-30
US20190153076A1 (en) 2019-05-23
AU2017261374A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
SG11201809778TA (en) Dna antibody constructs for use against pseudomonas aeruginosa
SG11201810640RA (en) Cd33 specific chimeric antigen receptors
SG11201804765UA (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201808979UA (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG11201810883TA (en) Combination therapy
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201805048SA (en) Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201811292RA (en) Compositions and methods for the depletion of cells